Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
Imagion Non-Executive Director Mike Harsh details how MagSense is the sixth way of imaging
MELBOURNE and SAN DIEGO — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announced that the
https://youtu.be/LI18OcgM9XM Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.